BS_C41DJZ1F
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 17.57555847568988
- age_years
- 13.37
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.496
- ANGIOGENESIS+0.426
- G2M_CHECKPOINT+0.387
- E2F_TARGETS+0.325
- WNT_BETA_CATENIN_SIGNALING+0.200
- KRAS_SIGNALING_UP+0.199
- COAGULATION+0.178
- MITOTIC_SPINDLE+0.174
- ALLOGRAFT_REJECTION+0.167
- HEDGEHOG_SIGNALING+0.132
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.622
- ADIPOGENESIS-0.447
- PROTEIN_SECRETION-0.437
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.433
- FATTY_ACID_METABOLISM-0.416
- PEROXISOME-0.412
- HEME_METABOLISM-0.407
- INTERFERON_ALPHA_RESPONSE-0.387
- MTORC1_SIGNALING-0.369
- BILE_ACID_METABOLISM-0.343
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 824433bf-151c-46ea-9ea7-f53813f66a97 | — | — | 0.829 |
| 2 | 9604472c-4956-4170-8ba7-419f3e8d7418 | — | — | 0.821 |
| 3 | MNG788 | — | — | 0.815 |
| 4 | SRR8943029 | — | — | 0.804 |
| 5 | BS_44A3ES23 | Med | Medulloblastoma | 0.801 |
| 6 | MNG1001 | — | — | 0.792 |
| 7 | BS_XG0DBWVT | high-grade glioma | — | 0.790 |
| 8 | DRR168520 | — | — | 0.779 |
| 9 | s_150203_3a | EPN | Supratentorial EPN | 0.779 |
| 10 | SRR2777217 | — | — | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.496 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.426 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.387 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.325 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.199 | Inavolisib | — uncovered |
| COAGULATION | 0.178 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.174 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.167 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.132 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.128 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.114 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.105 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.097 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.093 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.087 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.077 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.068 | Inavolisib | — uncovered |
| MYOGENESIS | 0.063 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.025 | Remibrutinib | — uncovered |